: The Markey Cancer Center (MCC ) Clinical l Research and Data a Management Shared Resource Facility (CRD M SRF ) coordinates and facilitates clinical cancer trials at the MCC . The major goals of the shared resource are to provide support of the clinical trial process , including implementing and regulating trials provide a centralized clinical trial l database , and integrate with the following: investigational pharmacy support , financial accounting , data safety monitoring , and quality assurance . This shared resource also assist s physician investigators in the design and subsequent conduct of clinical l trials through its support of the Investigator Initiated Trial Protocol Development Unit . It performs all regulatory reporting and quality assurance needed to comply with Good Clinical Practice in the performance of clinical trials . The CRDM SRF has Standard Operating Procedures for all its activities including training of all new faculty an d staff . From Ma y 2011 through April 2012 , 2,54 2 new patient s with cancer were seen at the MCC . Of these , 1,45 1 were from Appalachian Kentucky . During the s time period , the CRDM SRF administrated therapeutic cancer clinical l trials that engage d 25 3 (10% ) participants in therapeutic intent clinical trials . Importantly , 14 1 Appalachian patient s were engage d in therapeutic intent clinical research , a 10 % accrual rate from these disadvantaged and unique.

Public Health Relevance

The CRD M SR F provides central management an d oversight fo r coordinating , facilitating , and reporting on MCC cancer clinical trials . Th e CRDM SR F provides a central location for digital an d hard copy cancer protocols , a central database o f protocol-specific data , an update d lis t of active protocol s for investigators , an d protocol status reports . The CRDM SR F support s quality control functions , including education an d training service s for data managers and nurses and data auditing in support of the audit committee .

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA177558-02
Application #
8740641
Study Section
Subcommittee B - Comprehensiveness (NCI)
Project Start
Project End
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
2
Fiscal Year
2014
Total Cost
Indirect Cost
Name
University of Kentucky
Department
Type
DUNS #
City
Lexington
State
KY
Country
United States
Zip Code
40506
Wei, Xiaowei; Xu, Yong; Xu, Fang Fang et al. (2017) RelB Expression Determines the Differential Effects of Ascorbic Acid in Normal and Cancer Cells. Cancer Res 77:1345-1356
Cui, Jiajun; Xu, Wenhua; Chen, Jian et al. (2017) M2 polarization of macrophages facilitates arsenic-induced cell transformation of lung epithelial cells. Oncotarget 8:21398-21409
Wu, Yadi; Wang, Yu; Lin, Yiwei et al. (2017) Dub3 inhibition suppresses breast cancer invasion and metastasis by promoting Snail1 degradation. Nat Commun 8:14228
Wise, James T F; Wang, Lei; Zhang, Zhuo et al. (2017) The 9th Conference on Metal Toxicity and Carcinogenesis: The conference overview. Toxicol Appl Pharmacol 331:1-5
Carpenter, Brittany L; Liu, Jinpeng; Qi, Lei et al. (2017) Integrin ?6?4 Upregulates Amphiregulin and Epiregulin through Base Excision Repair-Mediated DNA Demethylation and Promotes Genome-wide DNA Hypomethylation. Sci Rep 7:6174
Jarrett, Stuart G; D'Orazio, John A (2017) Hormonal Regulation of the Repair of UV Photoproducts in Melanocytes by the Melanocortin Signaling Axis. Photochem Photobiol 93:245-258
Li, Liqing; Li, Xiang; Qi, Lei et al. (2017) The role of talin2 in breast cancer tumorigenesis and metastasis. Oncotarget 8:106876-106887
Kenlan, Dasha E; Rychahou, Piotr; Sviripa, Vitaliy M et al. (2017) Fluorinated N,N'-Diarylureas As Novel Therapeutic Agents Against Cancer Stem Cells. Mol Cancer Ther 16:831-837
Son, Young-Ok; Pratheeshkumar, Poyil; Divya, Sasidharan Padmaja et al. (2017) Nuclear factor erythroid 2-related factor 2 enhances carcinogenesis by suppressing apoptosis and promoting autophagy in nickel-transformed cells. J Biol Chem 292:8315-8330
Arnold, Susanne M; Chansky, Kari; Leggas, Markos et al. (2017) Phase 1b trial of proteasome inhibitor carfilzomib with irinotecan in lung cancer and other irinotecan-sensitive malignancies that have progressed on prior therapy (Onyx IST reference number: CAR-IST-553). Invest New Drugs 35:608-615

Showing the most recent 10 out of 281 publications